Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TISSEEL to Reduce Esophagojejunal Anastomosis Dehiscence in Total Gastrectomy
2024-519529-40-00Phase 3Authorised
- Sponsor
- Hospital Universitari Germans Trias i Pujol
- Start
- Jan 2025
- Modality
- Recombinant Proteins and Enzymes, Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised trial of tisseel in gastric adenocarcinoma (2 arms), sponsored by Hospital Universitari Germans Trias i Pujol. Primary endpoint: Esophagojejunal suture dehiscence within 7 days. Planned start Jan 2025; status: authorised.
02
Drugs
tisseel
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on 2024-519529-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519529-40-00.